Skip to main content

Advertisement

Fig. 2 | Breast Cancer Research

Fig. 2

From: Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

Fig. 2

a Immunohistochemical staining patterns of phosphatase and tensin homolog (PTEN). No immunostaining was detectable in breast carcinoma cells, but it was present in adjacent benign stromal cells (0; A), cytoplasmic immunostaining weak (1+; B), cytoplasmic immunostaining in carcinoma cells intermediate (2+; C), cytoplasmic immunostaining strong (3+; D) (scale bars = 50 μm). b Frequency of tumours with 0, 1+, 2+ and 3+ immunostaining. All images were taken at × 40 original magnification. c Frequency of PIK3CA/ERBB mutations, low expression of PTEN, and co-occurring PIK3CA/ERBB mutations and low expression of PTEN (i.e., PI3K pathway activated) in 45 baseline tumour biopsies that were evaluable for PTEN expression

Back to article page